Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.1.B40 - 11beta-hydroxysteroid dehydrogenase (NAD+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
11beta-hydroxysteroid dehydrogenase (nad+) deficiency
11 beta-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease.
Abnormalities of aldosterone synthesis and action in children.
Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation.
Cellular selectivity of aldosterone action: role of 11 beta-hydroxysteroid dehydrogenase.
Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families.
Endocrine causes of hypertension.
Fatal, low renin hypertension associated with a disturbance of cortisol metabolism.
Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man.
Heterogeneity of urinary steroid profiles in children with adrenocortical tumors.
Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension.
Mineralocorticoid hypertension and congenital deficiency of 11 beta-hydroxysteroid dehydrogenase in a family with the syndrome of 'apparent' mineralocorticoid excess.
Renin-Independent hypermineralocorticoidism.
Spironolactone-reversible rickets associated with 11 beta-hydroxysteroid dehydrogenase deficiency syndrome.
[11 beta-Hydroxysteroid dehydrogenase deficiency]
11beta-hydroxysteroid dehydrogenase deficiency
Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism.
ACTH Syndrome, Ectopic
Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome.
Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease enzymatic activity induced by ACTH.
Adenoma
Cortisol-secreting adrenal adenomas express 11beta-hydroxysteroid dehydrogenase type-2 gene yet possess low 11beta-HSD2 activity.
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.
Adrenal Hyperplasia, Congenital
Effect of hypercortisolism and ACTH on the metabolism of cortisol.
Hyper- and hypoaldosteronism.
Renin-Independent hypermineralocorticoidism.
Alkalosis
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease enzymatic activity induced by ACTH.
Asthma
A novel 11 beta-hydroxysteroid dehydrogenase inhibitor contained in saiboku-to, a herbal remedy for steroid-dependent bronchial asthma.
Magnolol stimulates steroidogenesis in rat adrenal cells.
beta-carotene 3-hydroxylase deficiency
Hyper- and hypoaldosteronism.
Breast Neoplasms
Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells.
Carcinoma
Expression of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in primary lung carcinomas.
Heterogeneity of urinary steroid profiles in children with adrenocortical tumors.
Cardiomegaly
Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation.
Cholestasis
Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis.
Choriocarcinoma
Analysis of the promoter of the NAD+ dependent 11 beta-hydroxysteroid dehydrogenase (HSD11K) gene in JEG-3 human choriocarcinoma cells.
Regulation of 11 beta-hydroxysteroid dehydrogenase type 2 activity and mRNA in human choriocarcinoma cells.
Cushing Syndrome
11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome.
Effect of glucocorticoid excess on the cortisol/cortisone ratio.
Endocrine causes of hypertension.
Human kidney 11 beta-hydroxysteroid dehydrogenase: regulation by adrenocorticotropin?
Renin-Independent hypermineralocorticoidism.
[Decreased activity of 11-beta-hydroxysteroid dehydrogenase in patients with Cushing's syndrome]
Diabetes Mellitus
Evaluation of hepatic 11 beta-hydroxysteroid dehydrogenase activity by cortisone acetate test in young adults with diabetes mellitus type 1.
Diabetes Mellitus, Type 2
Decreased expression of adipogenic genes in obese subjects with type 2 diabetes.
Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
Eczema
Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid.
Endocrine System Diseases
Endocrine causes of hypertension.
Endometrial Neoplasms
Modulation of 11 beta-hydroxysteroid dehydrogenase type 2 activity in Ishikawa cells is associated with changes in cellular proliferation.
Essential Hypertension
11beta-hydroxysteroid dehydrogenase type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities in the pathogenia of essential hypertension.
Corticosteroids in essential hypertension: multiple candidate loci and phenotypic variation.
Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.
Endogenous renal 11 beta-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension.
Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension.
Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks.
Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension.
Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: implications for the pathophysiology of hypertension.
The activities of 5 beta-reductase and 11 beta-hydroxysteroid dehydrogenase in essential hypertension.
[Endocrine hypertension]
Fetal Growth Retardation
Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation.
Genetic Diseases, Inborn
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Heart Failure
Glucocorticoid metabolism and the action of 11 beta-hydroxysteroid dehydrogenase 2 in canine congestive heart failure.
Inhibitors of 11 beta-hydroxysteroid dehydrogenase and 5 beta-steroid reductase in urine from patients with congestive heart failure.
Hyperaldosteronism
Endocrine causes of hypertension.
[Hypokalemia without arterial hypertension by licorice poisoning]
Hyperandrogenism
5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche.
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Hyperglycemia
Glucocorticoid "programming" and PTSD risk.
Hypertension
11 beta-hydroxysteroid dehydrogenase (11 beta-HSD-II) activity in human placenta: its relationship to placental weight and birth weight and its possible role in hypertension.
11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome.
11 beta-Hydroxysteroid dehydrogenase activity in hypertension and renal disease.
11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
11 beta-Hydroxysteroid dehydrogenase deficit: a rare cause of arterial Hypertension. Diagnosis and therapeutic approach in two young brothers.
11 beta-Hydroxysteroid dehydrogenase: a link between the dysregulation of cortisol metabolism and hypertension.
A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Association between a variant in the 11 beta-hydroxysteroid dehydrogenase type 2 gene and primary hypertension.
Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families.
Corticosteroid hypertension.
Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics.
Cortisol, hypertension and obesity: the role of 11 beta-hydroxysteroid dehydrogenase.
Decreased activity of 11 beta-hydroxysteroid dehydrogenase in mesenteric arteries of Dahl salt-sensitive rats.
Defects in cortisol metabolism causing low-renin hypertension.
Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
Effect of carbenoxolone on glucocorticoid metabolism and Na transport in toad bladder.
Endocrine causes of hypertension.
Endogenous 11 beta-hydroxysteroid dehydrogenase inhibitors and their role in glucocorticoid Na+ retention and hypertension.
Endogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in hypertension.
Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension.
Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension.
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11{beta}-hydroxysteroid dehydrogenase type 2 in a sex-specific manner.
Glucocorticoid "programming" and PTSD risk.
Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man.
Haemodynamic and metabolic effects of carbenoxolone in normal subjects and patients with renal impairment.
Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.
Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene.
Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11?-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell lines.
Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney.
Investigation of the mechanism of hypertension in apparent mineralocorticoid excess.
Mineralocorticoid hypertension and congenital deficiency of 11 beta-hydroxysteroid dehydrogenase in a family with the syndrome of 'apparent' mineralocorticoid excess.
Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
Mutations in the 11 beta-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth.
Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: implications for the pathophysiology of hypertension.
Placental 11 beta-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies.
Placental 11 beta-hydroxysteroid dehydrogenase and the programming of hypertension.
Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease enzymatic activity induced by ACTH.
Sodium status, corticosteroid metabolism and blood pressure in normal human subjects and in a patient with abnormal salt appetite.
The 11 beta-OHSD inhibitor, carbenoxolone, enhances Na retention by aldosterone and 11-deoxycorticosterone.
The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11beta-hydroxysteroid dehydrogenase: potential molecular mechanisms underlying the programming of hypertension in utero.
The role of 11 beta-hydroxysteroid dehydrogenase in the pathogenesis of hypertension.
Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man.
[11 beta-hydroxysteroid dehydrogenase type 2 activity in Chilean patients with hypertension]
[Aldosterone and 11 beta-hydroxysteroid dehydrogenase: role in arterial hypertension]
[Hypokalemia without arterial hypertension by licorice poisoning]
Hypoaldosteronism
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Hypokalemia
A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics.
Inhibition of 11 beta-hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringenin and some other compounds.
Infections
Active catabolism of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase in vivo is a necessary requirement for natural resistance to infection with Listeria monocytogenes.
Infertility
11 beta-Hydroxysteroid dehydrogenase enzyme activity in granulosa cells derived from ovarian follicles of in vitro fertilization patients.
Inflammatory Bowel Diseases
The Role and Regulation of the 11 Beta-Hydroxysteroid Dehydrogenase Enzyme System in Patients with Inflammatory Bowel Disease.
Insulin Resistance
Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
The metabolic syndrome X and peripheral cortisol synthesis.
The polygenetically inherited metabolic syndrome of WOKW rats is associated with insulin resistance and altered gene expression in adipose tissue.
Leukemia
Meeting Report:The 7th ESPE Growth Plate Working Group Symposium - EUROGROP June 27th 2007, Helsinki, Finland.
Liddle Syndrome
Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury.
Liver Cirrhosis
Down-regulation of hepatic and renal 11 beta-hydroxysteroid dehydrogenase in rats with liver cirrhosis.
Increased apical targeting of renal epithelial sodium channel subunits and decreased expression of type 2 11beta-hydroxysteroid dehydrogenase in rats with CCl4-induced decompensated liver cirrhosis.
Liver Diseases
11 beta-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease.
Metabolic Syndrome
Global 11 Beta-Hydroxysteroid Dehydrogenase Activity Assessed by the Circulating Cortisol to Cortisone Ratio is Associated with Features of Metabolic Syndrome.
[11beta-hydroxysteroide dehydrogenases. Recent advances]
[Novel transgenic mouse model of the metabolic syndrome]
Mineralocorticoid Excess Syndrome, Apparent
Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone.
[Liquorice-induced hypertension and hypokalaemia].
Neoplasms
11 beta-hydroxysteroid dehydrogenase type II in human colon: a new marker of fetal development and differentiation in neoplasms.
Decreased expression of adipogenic genes in obese subjects with type 2 diabetes.
Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPAR? Regulation in Hyperlipidemic and Hypertensive Conditions.
Presence of 11 beta-hydroxysteroid dehydrogenase enzyme in the human prostate tumor cell line LNCaP.
Renin-Independent hypermineralocorticoidism.
Obesity
11 beta-Hydroxysteroid dehydrogenase activity in hypothalamic obesity.
Cortisol, hypertension and obesity: the role of 11 beta-hydroxysteroid dehydrogenase.
Decreased expression of adipogenic genes in obese subjects with type 2 diabetes.
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Obesity, Abdominal
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Omental adipose tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women.
The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis.
Osteoporosis
The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis.
Osteosarcoma
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Ovarian Neoplasms
Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.
Pheochromocytoma
Endocrine causes of hypertension.
Pituitary Neoplasms
Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation.
Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors.
Polycystic Ovary Syndrome
5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche.
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Pre-Eclampsia
11 beta-Hydroxysteroid dehydrogenase and its inhibitors in hypertensive pregnancy.
Prostatic Neoplasms
11 beta-Hydroxysteroid dehydrogenase and tissue specificity of androgen action in human prostate cancer cell LNCaP.
Psoriasis
Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid.
Respiratory Distress Syndrome
Increased expression of 11 beta-hydroxysteroid dehydrogenase type 2 in the lungs of patients with acute respiratory distress syndrome.
Rickets
Spironolactone-reversible rickets associated with 11 beta-hydroxysteroid dehydrogenase deficiency syndrome.
Stillbirth
Mutations in the 11 beta-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth.
Vaccinia
Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus.